Celldex Therapeutics Inc (CLDX NASDAQ) stock market data APIs
$20.4164
-0.41(-2%)
as of June 12, 2025
Try our APIs with
free plan!
Celldex Therapeutics Inc Financial Data Overview
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Prev. Close
20.4164
Open
20.0014
High
21.2287
Low
19.4862
52 wk Range
14.4-47
Market Cap
1 356 M
Shares Outstanding
66 394 K
Revenue
7 559 K
EPS
-0.81
Beta
1.137
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Celldex Therapeutics Inc data using free add-ons & libraries
Get Celldex Therapeutics Inc Fundamental Data
Celldex Therapeutics Inc Fundamental data includes:
- Net Revenue: 7 559 K
- EBITDA: -213 940 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: -0.69
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celldex Therapeutics Inc News
New
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality...
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Celldex Therapeutics, Inc. Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no...
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Xenon Pharmaceuticals (XENE). Shares have added about 8.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continu...
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
Celldex Therapeutics, Inc. Company to host webcast on Thursday, June 12 at 6:00 pm ET HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Compan...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
